Primary outcomes:HbA1cReduction in diabetes medication useSecondary outcomes:Diabetes remission rates.Liver function test scores, including: NAFLD-LFS r, NAFLD-NFS s, FLI, FSI t, FIB-4 u, APRI v;Visceral adiposity: MRI wLiver fat percentage: MRI-PDFF xWeight loss, BMI y, WC z, HOMA2-IR aaLiver enzymes: ALT ab, AST ac, GGT ad;Glycemic variability measures: CV ae, MAGE af;Inflammatory markers: hs-CRP ag, WBC ah, ESR aiFerritin levels. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.